• Neurogene Inc NGNE.OQ reported a quarterly adjusted loss of 99 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.51. The mean expectation of six analysts for the quarter was for a loss of $1.13 per share. Wall Street expected results to range from $-1.26 to $-1.04 per share.

• Reported revenue was zero​; analysts expected zero.

• Neurogene Inc's reported EPS for the quarter was a loss of 99 cents​.

• The company reported a quarterly loss of $19.51 million.

• Neurogene Inc shares had fallen by 37.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Neurogene Inc is $46.00

This summary was machine generated from LSEG data March 24 at 09:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)